{"id":2556,"date":"2018-02-20T15:21:37","date_gmt":"2018-02-20T09:51:37","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2556"},"modified":"2023-02-10T11:22:11","modified_gmt":"2023-02-10T05:52:11","slug":"notizia-pharmaceutical-latest-updates","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates","title":{"rendered":"CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Rice University researchers tested CRISPR to cure sickle cell, now preparing for upcoming challenges<\/strong><\/p>\n<p style=\"text-align: justify;\">A team of Researchers led by <strong>Rice University<\/strong> has recently tested <strong>CRISPR<\/strong> to correct the sickle cell mutation in up to <strong>40%<\/strong> of the total stem cell samples taken from affected patients. Although the results are quite promising, it also highlights the challenges that must be cleared before the gene editing therapy can become a reliable and effective option for patients with blood disorders.<\/p>\n<p style=\"text-align: justify;\"><strong>FDA rejected the Apricus Biosciences\u2019 erectile dysfunction cream for the second time<\/strong><\/p>\n<p style=\"text-align: justify;\">For the second time, FDA has issued a complete response letter and rejected the Apricus Biosciences\u2019 highly anticipated drug (<strong>Vitaros<\/strong>) meant for topical erectile dysfunction (ED) drug, causing a major slump in its share price. Apricus stocks were on the rise over the last few days on anticipation of a positive verdict for its lead drug candidate, but after the letter from FDA, all the gains were wiped out within hours driving its shares down <strong>73%<\/strong> into penny stock territory.<\/p>\n<p style=\"text-align: justify;\"><strong>Generating immune attack against cancer by using stem cells<\/strong><\/p>\n<p style=\"text-align: justify;\">Scientists at Stanford University believe that <strong>Induced pluripotent stem cells<\/strong> (iPSCs) can help the immune system to recognize and attack the cancer cells making them a prime candidate for regenerative medicine. They have even tested the concept in mouse models of breast cancer. When they injected mice with inactivated IPSCs, the animals\u2019 immune systems initiated an attack against cancer and prevented relapse after tumors had been removed, as per the study published in the journal Cell Stem Cell.<\/p>\n<p style=\"text-align: justify;\"><strong>Celgene spinoff celularity debuts with big names, holding big bucks for bright future<\/strong><\/p>\n<p style=\"text-align: justify;\">Celgene\u2019s spinoff Celularity has recently bagged a considerable amount of funding with some of the biggest names in biotech and Silicon Valley for its work in cancer. Growing under the leadership of <strong>Dr. Bob Hariri<\/strong> (founder and CEO celularity) company has raised a whopping <strong>USD 250 million<\/strong> accelerating its placental cell-based treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rice University researchers tested CRISPR to cure sickle cell, now preparing for upcoming challenges A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle cell mutation in up to 40% of the total stem cell samples taken from affected patients. Although the results are quite promising, it also highlights [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17434,32],"tags":[1431,1118,155,1434,647,204,1435,1433,338,381,730,1230,1261,706,1430,1432],"industry":[17225],"therapeutic_areas":[17557,17228],"class_list":["post-2556","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-facts-and-figures","category-notizia","tag-apricus-bioscience","tag-business-research","tag-celgene","tag-celularity","tag-crispr","tag-delveinsight","tag-dr-bob-hariri","tag-induced-pluripotent-stem-cells","tag-ipscs","tag-market-research","tag-notizia","tag-pharma-consultancy","tag-pharma-consulting","tag-pharmaceutical-industry","tag-rice-university","tag-vitaros","industry-pharmaceutical","therapeutic_areas-male-health","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CRISPR for sickle cell; Vitaros rejection; Celgene&#039;s deal<\/title>\n<meta name=\"description\" content=\"A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle cell mutation in up to 40% of stem cell from patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR for sickle cell; Vitaros rejection; Celgene&#039;s deal\" \/>\n<meta property=\"og:description\" content=\"A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle cell mutation in up to 40% of stem cell from patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-20T09:51:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T05:52:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CRISPR for sickle cell; Vitaros rejection; Celgene's deal","description":"A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle cell mutation in up to 40% of stem cell from patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates","og_locale":"en_US","og_type":"article","og_title":"CRISPR for sickle cell; Vitaros rejection; Celgene's deal","og_description":"A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle cell mutation in up to 40% of stem cell from patients.","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-02-20T09:51:37+00:00","article_modified_time":"2023-02-10T05:52:11+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates","url":"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates","name":"CRISPR for sickle cell; Vitaros rejection; Celgene's deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-02-20T09:51:37+00:00","dateModified":"2023-02-10T05:52:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle cell mutation in up to 40% of stem cell from patients.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharmaceutical-latest-updates#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>","<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Apricus Bioscience<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celularity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dr. Bob Hariri<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Induced pluripotent stem cells<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">iPSCs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rice University<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vitaros<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Apricus Bioscience<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">Celularity<\/span>","<span class=\"advgb-post-tax-term\">CRISPR<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Dr. Bob Hariri<\/span>","<span class=\"advgb-post-tax-term\">Induced pluripotent stem cells<\/span>","<span class=\"advgb-post-tax-term\">iPSCs<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">Rice University<\/span>","<span class=\"advgb-post-tax-term\">Vitaros<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Feb 20, 2018","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Feb 20, 2018 3:21 pm","modified":"Updated on Feb 10, 2023 11:22 am"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2556"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2556\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2556"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2556"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}